Oramed Pharmaceuticals, Inc. Stock OTC Bulletin Board
Equities
US68403P1049
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-15 | Compugen Names David Silberman CFO | MT |
05-13 | Oramed Pharmaceuticals Inc. Announces Resignation of David Silberman as Chief Financial Officer, Effective July 12, 2024 | CI |
Sales 2024 * | 750K 1.03M | Sales 2025 * | 2M 2.73M | Capitalization | 89.79M 123M |
---|---|---|---|---|---|
Net income 2024 * | - 0 | Net income 2025 * | -14M -19.14M | EV / Sales 2024 * | 120 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 44.9 x |
P/E ratio 2024 * |
-221
x | P/E ratio 2025 * |
-6.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.73% |
Managers | Title | Age | Since |
---|---|---|---|
Miriam Kidron
FOU | Founder | 83 | 02-04-11 |
Nadav Kidron
CEO | Chief Executive Officer | 50 | 02-04-11 |
Joshua Hexter
COO | Chief Operating Officer | 53 | 13-04-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nadav Kidron
CEO | Chief Executive Officer | 50 | 02-04-11 |
Miriam Kidron
FOU | Founder | 83 | 02-04-11 |
Leonard Sank
BRD | Director/Board Member | 59 | 07-10-22 |
1st Jan change | Capi. | |
---|---|---|
+55.70% | 55.7B | |
+41.08% | 39.91B | |
-5.39% | 39.57B | |
-5.56% | 28.16B | |
+16.46% | 26.3B | |
-20.56% | 18.94B | |
+33.03% | 12.17B | |
+25.85% | 12.12B | |
+2.72% | 12.12B |